COX-2 overexpression is known to be an important mechanism in gastric carcinogenesis. Previously we have found that early-onset gastric cancer has a unique COX-2 low-expressing phenotype that differs significantly from that of the frequent overexpression seen in conventional gastric cancers. To investigate whether the COX-2 -765 G4C promoter polymorphism (known to lead to a reduction of COX-2 promoter activity in the colon) may explain this difference in expression, we carried out single-nucleotide polymorphism (SNP) analysis of 241 gastric cancers, including early-onset gastric cancer, conventional gastric cancers and gastric stump cancers, as well as in 100 control patients, using real-time PCR and sequence analysis, and correlated these findings with COX-2 expression using immunohistochemistry. We found that the C allele was present in 30% of early-onset gastric cancers, 24% of conventional gastric cancer, 23% of stump cancers, in contrast to 41% in the control group. There was a statistically significant difference in the presence of the C allele in patients with gastric cancer compared with the control group (P ¼ 0.007), with the C allele being associated with protection against gastric cancer. However, there was no significant difference between the early-onset, conventional and stump gastric cancer groups. Interestingly, there was no correlation between the presence of the C allele and a difference in COX-2 expression. In summary, we show that the COX-2 -765 G allele promoter polymorphism is significantly associated with gastric cancer when compared with the normal control group, but does not appear to be related directly to COX-2 expression pattern in gastric cancer. Although early-onset gastric cancers appear to have a unique COX-2 expression pattern when compared with conventional gastric cancer, the exact mechanism by which this occurs is yet to be elucidated.
Gastric cancer is the second most common cause of cancer-related death in the world. 1 It exists as two main histological types, diffuse and intestinal, as described by Laurén, 2 and is thought to result from a combination of environmental factors and accumulation of specific genetic alterations, and consequently mainly affects older patients. COX-2 is an inducible enzyme and produces prostaglandins in response to various inflammatory stimuli or growth factors. Expression of COX-2 is elevated in gastric adenocarcinomas as compared with in the nonneoplastic mucosa, 3 and is predominantly expressed in intestinal-type gastric carcinomas and its precursor lesions. 4, 5 COX-2 overexpression has been associated with inhibition of apoptosis, 6 increased metastatic potential 7 and neoangiogenesis. 8 Interestingly, we have found previously 9 that COX-2 expression varies significantly between early-onset gastric cancers (presenting at r45 years old) and conventional cancers (presenting 445 years old), with COX-2 overexpression occurring rarely in early-onset gastric cancers. In light of studies showing reduced risk of gastric cancer in non-steroidal anti-inflammatory drug users, [10] [11] [12] our results may have clinical implications, as they suggest that this reduced risk may apply only to gastric cancers in older patients, as COX-2 does not appear to play an important role in early-onset gastric cancer. It also implies that genetic changes typical for conventional tumors more readily induce COX-2 expression than those associated with earlyonset gastric cancer. The mechanism behind this difference in COX-2 regulation and expression in these sub-types of gastric cancer is intriguing.
Transcriptional regulation has been shown to be the major mechanism in regulating the expression of COX-2, although posttranscriptional mechanisms such as increased stability of COX-2 mRNA (eg, via HuR) also seem important. 9 The expression of COX-2 is regulated by a complex signal transduction pathway in which many nuclear proteins interact with the COX-2 promoter region and play a decisive role in gene transcription. 13 Naturally occurring singlenucleotide polymorphisms (SNPs) in the COX-2 promoter may therefore have a great impact on gene transcriptional activity by altering the binding capability with certain nuclear proteins, resulting in inter-individual variability in susceptibility to cancer and in response to the treatment of patients with COX-2 inhibitors. Indeed, Papafili et al 14 have described a polymorphism in the promoter region of COX-2, characterized by a guanine (G) to cytosine (C) transition at position À765 (À765G4C). This polymorphism appears to disrupt a Stimulatory protein 1 (Sp1)-binding site, which is considered to be a positive activator of transcription and leads to a 30% reduction of COX-2 promoter activity in vitro 14 and is also known to be associated with decreased COX-2 expression in the colon. 15 In this study, we examine the distribution of the COX-2 À765 G4C polymorphism in 241 gastric cancers (including early-onset gastric cancer, conventional gastric cancer and gastric stumps cancers) and 100 control patients using real-time PCR with MGB fluorescent probes and sequence analysis, and investigate the relationship with COX-2 expression in gastric cancer using immunohistochemistry. 17 
Materials and methods

Patients
DNA Isolation
DNA was isolated from formalin-fixed tissue using the QIAamp DNA Mini kit (Qiagen, Venlo, the Netherlands) or the Puregene DNA Isolation kit (Gentra, MN, USA) according to the manufacturer's instructions. Normal tissue was obtained from a tumor-free lymph node, or where necessary from tissue with a small component of neoplastic cells. DNA concentrations were measured using the NanoDrop spectrophotometer (Isogen Life Science, IJsselstein, the Netherlands).
Real-time PCR
The polymorphism 765G4C in the promoter region of COX-2 was detected using LightCycler 2.0 (Roche, Mannheim, Germany) with 5 0 -CATTAACTATTTAC AGGGTAACTGCTTAGG-3 0 and 5 0 -CCCCCTCCTTG TTTCTTGGA-3 0 (Applied Biosystems, Foster City, USA) as primers and MGB fluorescent probes 6-FAM-5 0 -CTTTCCCGCCTCTCT-3 0 and TET-5 0 -CTTT CCCCCCTCTCT-3 0 (Applied Biosystems) in a 20 ml reaction mixture containing 10 ml of QuantiTect Probe PCR Master Mix (Qiagen, Leusden, the Netherlands), 10 pmol forward and reverse primer, 
Sequencing
To confirm our result of real-time quantitative PCR, 10% of the samples were sequenced. The promoter region was amplified using primers 5 0 -GCATACGTT TTGGACATTTAG-3 0 (forward) and 5 0 -CTACCTTCA GTGTACATAGC-3 0 (reverse) (Applied Biosystems). PCR products were purified using the QIAquick PCR Purification kit (Qiagen) according to the manufacturer's instructions. The sequences were analyzed on an ABI 3100 automated sequencer (Applied Biosystems) using the ABI Big Dye Terminator Cycle Sequence kit (Applied Biosystems) and the forward internal primer 5 0 -GTTTTGGACATTTAGCGTCC-3 0 (Applied Biosystems). Sequences of control samples obtained from the Pathology Department at the Johns Hopkins Medical Institute (Baltimore, USA) were also confirmed by this method.
Immunohistochemistry COX-2 immunohistochemistry was carried out on tissue microarrays (TMA) when available (n ¼ 184) and as described previously. 9 In 51 cases, it was performed on whole-tissue sections and in six cases tumor tissue was no longer available or unassessable on the TMA. Sections (4 mm) were deparaffinized and antigen was retrieved by 10 min of boiling in 0.01 M Na-citrate buffer (pH 6), followed by immersion in 0.03% hydrogen peroxide in methanol for 20 min. Non-specific binding sites were blocked 
COX-
by preincubation with and 0.01 M Tris, 0.1 M MgCl 2 , 0.5% Tween-20, 1% BSA and 5% normal goat serum for 1 h. The primary antibody was incubated using monoclonal COX-2 antibody at a dilution of 1:100 (Cayman Chemical Co., Ann Arbor, USA) at 41C overnight. Antibody binding was visualized using the Powervision þ poly-HRP detection system (ImmunoVision Technologies, Daly City, CA, USA) with 3,3-amino-9-ethylcarbazole (Sigma-Aldrich, Zwijndrecht, the Netherlands) as chromogen. Sections were counterstained with hematoxylin.
Scoring
The overall score of the tumor was the highest score found. The following scoring criteria of the tumor cells were used (Figure 1 ): 0, no staining; 1, weak diffuse cytoplasmic staining (may contain stronger intensity in less than 10% of the cancer cells); 2, moderate to strong granular cytoplasmic staining in 10-50% of the cancer cells; 3, 450% of the tumor cells stained with strong intensity. Scores 0 and 1 were categorized as 'COX-2 low' and scores 2 and 3 as 'COX-2 high' for statistical analyses. 18 No slides showed increased negative staining around the edges, and the age of the block had no influence on immunohistochemical staining.
Statistics
The SPSS 14.0 software package was used for statistical analysis. A w 2 -test was applied to the groups of gastric cancer to determine whether there was a statistical difference (Po0.05) between the presence of the C or G allele, as well as to examine the correlation between the presence of the C or G allele and COX-2 overexpression. A binary logistic regression model was used to adjust for potential confounding factors such as location (cardia or body in the case of early-onset gastric cancer and conventional gastric cancer) and histological type.
Results
Distribution of COX-2 À765 GC Polymorphism
The distribution of the COX-2 À765 promoter polymorphism was examined in 241 cases of gastric cancer, including 96 conventional gastric cancers, 115 early-onset gastric cancers and 30 gastric stump cancers, as well as in 100 healthy control cases, as can be seen in Table 2 . All genotypic distributions were in Hardy-Weinberg equilibrium (PZ0.05).
Of note the frequencies of the three genotypes (GG, GC and CC) were similar in early-onset gastric cancer, conventional gastric cancer and stump cancer, with no statistical difference between these gastric cancer groups in a w 2 -test. There was a statistically significant difference in the presence of the C allele in patients with gastric cancer (earlyonset gastric cancer, conventional gastric cancer and gastric stump cancer) compared with the control group (P ¼ 0.007), with the C allele associated with protection against gastric cancer.
There was also no association between the presence of any one polymorphism and histological type.
Cox-2 Expression in Gastric Cancer
Expression of COX-2 was assessed by immunohistochemistry in 235 of the gastric cancer samples, which were subject to polymorphism analysis, including early-onset gastric cancer, conventional gastric cancer and stump cancers, as can be seen in Table 3 . Of note, 94 of the early-onset gastric cancers and 90 cases of conventional gastric cancers described in Table 3 have been published previously, 9 where a statistically significant difference (Po0.001) was seen between early-onset gastric cancer and conventional gastric cancer, with early-onset gastric cancer having a COX-2 lowexpressing phenotype as well as a statistically significant association with the intestinal phenotype (Po0.001). This statistical difference remained COX-2 promoter polymorphism -765 G4C and gastric cancers R Sitarz et al when adjusted for histology and location using a binary logistic regression model (Po0.001). They have been included here for comparison with the gastric stump cancers and for the association with COX-2 -765 polymorphism. We found that the COX-2 expression profile of gastric stump cancers bears similarity to that of conventional gastric cancers, with no statistical difference between these two groups (P ¼ 0.25), and thus the early-onset gastric cancer group remained significantly different from gastric stump and conventional gastric cancers with respect to COX-2 expression (Po0.001). There was no significant correlation between COX-2 expression and À765 genotype (P ¼ 0.22).
Discussion
The diseases in which a role for COX-2 has been shown are usually characterized by varying individual and even ethnic susceptibility, implying the role of genetic factors. 19 The specific function of COX-2 in the formation of prostaglandins makes it a strong candidate for increasing susceptibility to common cancers. Genetic polymorphisms altering the level of protein expressed would be anticipated to have a substantial influence on disease activity. Several SNPs in COX-2 have been reported previously, but many of these polymorphisms seem to be functionally insignificant and not associated with susceptibility to cancer. [20] [21] [22] However, it has been shown that the À765G4C COX-2 polymorphism has been reported to disrupt an Sp1-binding site and displays a lower promoter activity, 14 and interestingly, a higher COX-2 expression has been found in the normal mucosa of patients with FAP who carried the À765GG polymorphism, 15 than carriers of the C allele. These findings awaken curiosity within the field of gastric cancer, as to whether it may also play a role here.
In this study, we sought to identify the distribution of the À765 G4C polymorphism in the promoter of the human COX-2 gene in early-onset gastric cancer, conventional gastric cancer and gastric stump cancers. In addition, we looked at the effect of this polymorphism on COX-2 expression. We found that the G allele was associated with gastric cancer, including early-onset gastric cancer, conventional gastric cancer and gastric stump cancers, with the C allele showing a protective effect, and there was no significant difference between histological types. In addition, we found no correlation between the presence of the G allele and overexpression of the COX-2 protein in either gastric cancer or normal mucosa.
An association between the 765C allele and increased risk of esophageal squamous cell carcinoma has been demonstrated previously, 23 and an increased risk of colon cancer in Singapore Chinese who consume high amounts of n-6 polyunsaturated fatty acids has also been associated with this polymorphism. 24 However, a study in Japan showed no association between the À765G4C polymorphism and risk of colorectal cancer. 25 The role of this polymorphism in gastric cancer has been variable and the literature is inconclusive. Liu et al 26 found that subjects carrying the 1195AA genotype, another COX-2 promoter polymorphism, had an increased risk of gastric cancer and a significant increase in COX-2 expression; however, they failed to show any association with the À765G4C polymorphism and gastric cancer. This may be due the fact that the variant genotypes (CC) of the À765G4C polymorphism were rare in the population of their study (o1%), whereas in our study group, we saw the CC genotype in 9% of our control group (which consisted of 100 healthy males as described previously; Westerveld et al 17 ) . Additional controversy in the literature lies with a study by Pereira et al, 27 where an association with the C allele and gastric cancer was reported. This is unexpected, as the described decrease in expression has been reported in association with the C allele. 14, 15 One would thus expect that the G allele, is responsible for conferring an increased susceptibly to gastric cancer. However, contrary to the study by Brosens et al where they found a correlation between COX-2 expression in the normal mucosa and the À765 polymorphism, we find no relationship between the À765 COX-2 polymorphism and expression in either the tumor or normal tissue, and thus the situation in the stomach does not appear to mirror that in the intestine in this regard. However, despite showing an association with the C allele and gastric cancer, Pereira et al also describe that their results revealed a possible protective role for -765C carriers, a finding that is confirmed with statistical significance in our current study. Previous studies have shown that SNPs in the COX-2 gene vary greatly in different ethnic populations, 14, 15 providing a possible explanation for the discrepancy within the literature in relation to gastric cancer.
In summary, we show that the COX-2 -765 G allele promoter polymorphism is significantly associated with gastric cancer, including early-onset gastric cancer, conventional gastric cancers and gastric stump cancer, when compared with the normal control group, but does not appear to be related directly to COX-2 expression patterns in the stomach. Although early-onset gastric cancers appear to have a unique COX-2 expression pattern when compared with conventional gastric cancer, the exact mechanism by which this occurs is yet to be elucidated. samples. We also thank Sjoerd Repping at the Endocrinology Department, Academic Medical Centre, Amsterdam, for providing the control group, and Professor Penti Sipponen for supplying the gastric cancer samples from Finland. Robert Sitarz, the first author, was funded by the Stella Major Foundation.
